Skip to Content
Merck

SML4254

AT7519

≥98% (HPLC), powder, CDK inhibitor

Synonym(s):

AT 7519, AT-7519, AT7519, N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide, 4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide, 4-[(2,6-Dichlorobenzoyl)amino]-N-4-piperidinyl-1H-pyrazole-3-carboxamide

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C16H17Cl2N5O2
CAS Number:
Molecular Weight:
382.24
MDL number:
NACRES:
NA.21
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

AT7519, ≥98% (HPLC), powder, CDK inhibitor

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Application

AT7519 may be used to study its effects on cell viability and proliferation, cell cycle, apoptosis and pyroptosis in human glioblastoma cells.

Biochem/physiol Actions

AT7519 is a potent and selective cyclin dependent kinase (CDK) inhibitor (CDK5-p35/CDK2-CycA/CDK4-CycD1/CDK1-CycB IC50 = 18/44/67/190 nM; IC50 >10 μM against Aurora A, IR, MEK1, PDK1, c-abl) with antiproliferative activity in cancer cultures (IC50 = 82 nM/HCT116, 350 nM/A2780) and antitumor efficacy in mice in vivo (86% inhibition of A2780 xenograft tumor growth post 8-day treatment at 7.5 mg/kg b.i.d. i.p., 87% inhibition of HCT116 xenograft tumor growth post 10-day treatment at 9.1 mg/kg b.i.d. i.p.).

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L Santo et al.
Oncogene, 29(16), 2325-2336 (2010-01-27)
Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent kinases (CDKs) and their cyclin partners. Overexpression of individual complexes are reported in multiple myeloma (MM), making them attractive therapeutic targets. In
Paul G Wyatt et al.
Journal of medicinal chemistry, 51(16), 4986-4999 (2008-07-29)
The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions
Matthew S Squires et al.
Molecular cancer therapeutics, 8(2), 324-332 (2009-01-29)
Cyclin-dependent kinases (CDK), and their regulatory cyclin partners, play a central role in eukaryotic cell growth, division, and death. This key role in cell cycle progression, as well as their deregulation in several human cancers, makes them attractive therapeutic targets

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service